UBS and Citi maintain buy ratings on AstraZeneca ahead of its Q1 2026 results due April 29. UBS highlights strong momentum in cancer drugs Imfinzi, Tagrisso, and Calquence but notes challenges with Farxiga due to US wholesaler destocking and mandatory price cuts on some drugs in China. AstraZeneca is also preparing for launches of new drugs camizestrant and baxdrostat, which may increase costs. Citi is more optimistic, raising its price target and earnings growth forecast, boosted by positive developments in camizestrant and tozorakimab. Both banks see significant upside potential in AstraZeneca shares.
AstraZeneca PLC will announce its Q2 2026 earnings on July 27, following a strong Q1 with 12.5% revenue growth to $15.29 billion. Key growth driver Enhertu saw a 39.4% year-over-year revenue increase, reaching $831 million, and recently gained EU app...
AstraZeneca has agreed to pay $600 million upfront and up to $1.5 billion total for global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer with a specific genetic mutation ...
AstraZeneca has agreed to pay $600 million upfront, with up to $900 million more based on milestones, to acquire global rights to Zegfrovy, a lung cancer pill developed by China's Dizal Pharmaceutical. The drug targets non-small cell lung cancer pati...
HSBC downgraded AstraZeneca from 'buy' to 'hold' following the failure of its Wainua phase III trial for a heart disease treatment, which missed its primary endpoint. This trial was a major part of HSBC's positive outlook, and its failure has led to ...
UBS maintains a 'buy' rating on AstraZeneca ahead of its Q2 results due on July 27, expecting solid performance but no increase in full-year guidance. The bank forecasts 2026 revenue of $63.3 billion and core earnings per share of $9.48, with a margi...
